Page 177 - CW E-Magazine (5-12-2023)

CPHI Barcelona 2023

‘Packaging & Machinery’ section for
its AutoMAP pharma gas measurement
system for high or low concentrations
of oxygen in modified atmosphere
packaging.

In the ‘Supply Chain Excellence’
category, Catalent came out top for its
‘Case Management Services’, which
provides end-to-end professional supply
chain management and orchestration
for autologous and allogeneic cell and
gene therapies.

A comprehensive EDC solution Innovation’ category was React4Life’s in bold climate action and decarbonisa-
from Lambda Therapeutic Research, MIVO (multi in vitro organ) patented tion of the pharmaceutical value chain.
that enhances research efficiency and organ-on-a-chip. This can host and
streamlines data management was culture 3D human biological cells or InSyBio won the top prize in the
selected as the winner in the ‘Regula- tissues under fluid dynamic conditions ‘Start-Up Initiative’ category for its
tory Compliance’ category. as in vivo, overcoming the limitations ability to revolutionise the medical
of current pre-clinical assays while field, clinical trials and food/nutrition
In the ‘Drug Delivery & Device reducing animal testing. industries through its targeted bio-
Innovation’ category, the winner was marker discovery.
Medicsen’s Smartpatch – a wearable Schneider Electric was judged the
patch that uses ultrasound to deliver winner for the ‘Sustainability’ category The winner of the ‘Heart of Pharma’
drugs subcutaneously, avoiding needles thanks to its Energize programme that award was Merck KGaA – chosen for
and cannulas to create a unique drug enables a collaboration between 18 its Embracing Carers initiative that
delivery system that ensures patient global pharmaceutical companies to col- recognise the role that family carers
comfort. The winner in the ‘Accelerating lectively engage hundreds of suppliers play in society.

REGIONALISATION
Seqens seeks to strengthen India operations

Seqens, a French manufacturer of ness contributing over two-third of the
active ingredients and pharmaceutical revenues. “India is an important plat-
intermediates, is ramping up its R&D form for us in terms of production as
and manufacturing activities in India. well development. We have production
“We have been in India for only four of intermediates and APIs there. And
years now, but it’s a growing business we also have R&D which we want to
and the opportunity is tremendous,” grow, especially for the generics busi-
said Mr. Pierre Luzeau, President & ness,” said Mr. Luzeau.
CEO of the company in an exclusive
interaction with this magazine at the Mr. Christophe Eychenne-Baron,
CPHI Barcelona. the company’s R&D Director, informed
Mr. Pierre Luzeau that the Seqens R&D centre in Pune is
As an integrated manufacturer and In its pharma business, the company equipped with highly qualified person-
supplier across the entire value chain, has a portfolio of around 200 APIs nel and skillsets to develop new generic
Seqens offers a broad portfolio of while it develops new molecular enti- APIs and development & validation
active ingredients, pharmaceutical ties through its CDMO activities. The of analytical methods. “We will invest
intermediates, and speciality chemicals company has a turnover of around more in R&D with additional Ph.D.s,
including personal care ingredients. €1.4-bn, with the pharma related busi- engineers and technicians being hired

Chemical Weekly December 5, 2023 177

Contents Index to Advertisers Index to Products Advertised